Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability

• DOI: 10.1007/s00534-012-0531-9
• Publication Date: 2012-07-20T13:13:17Z
• Authors: Yuzo Umeda; Takeshi Nagasaka; Yoshiko Mori; Hiroshi Sadamori; Dong‐Sheng Sun; Susumu Shinoura; Ryuich Yoshida; Daisuke Satoh; Daisuke Nobuoka; Masashi Utsumi; Kazuhiro Yoshida; Takahito Yagi; Toshiyoshi Fujiwara
• Keywords: Microsatellite Instability

Abstract Background The discovery of practical biomarkers is important to realize personalized medicine for patients with malignant neoplasias, including colorectal cancer (CRC). Purpose aim this study was determine reliable prognostic by the analysis resectable liver metastases (CRLM). Methods Genomic DNA obtained from CRLM tissues a cohort 126 curative hepatic resection. KRAS / BRAF mutation spectrum and microsatellite instability (MSI) status were successfully analyzed in 100 these findings examined relation patients' clinical outcomes. Results consisted 46 synchronous 54 metachronous metastasis. Overall survival disease‐free at 5 years 57.4 24.9 %, respectively. MSI revealed that none specimens showed any evidence MSI. By KRAS/BRAF analysis, divided into 3 groups; ‐mutant ( ‐Mt; n = 27), 3), wild‐types both genes (Wild‐type; 70). In ‐Mt significantly poorer prognoses compared Wild‐type patients. Furthermore, although population small, had significant negative impact on survival. Conclusions study, all tumors non‐MSI tumors, suggesting primary CRC would rarely reveal metastatic potential. mutations are suggested be poor factors CRLM. Genetic information has an essential role as marker could contribute decisions treatment strategy